Please login to the form below

Not currently logged in
Email:
Password:

antitrust

This page shows the latest antitrust news and features for those working in and with pharma, biotech and healthcare.

It’s only money

It’s only money

problem breached European Union competition rules - this ruling upheld a 2014 decision by Italy’s antitrust authority that the drugmakers colluded to boost sales of Lucentis by discrediting the cheaper Avastin

Latest news

More from news
Approximately 4 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • Risky business for pharma Risky business for pharma

    to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... Villareal also cited “[c] ompetition and antitrust issues. as a global risk

  • Deal Watch October 2015 Deal Watch October 2015

    This deal will combine the second and third largest drug store operators in the US and as a result it will no doubt be scrutinised by the US antitrust authorities. ... Echoing some of the hefty termination provisions we saw last year in big pharma deals,

  • Pharma deals in July 2015 Pharma deals in July 2015

    However, Teva's deal with Allergan is not over yet. It is subject to review by antitrust regulators of the combined generics portfolio.

  • Pharma deals in June 2015 Pharma deals in June 2015

    When GSK acquired two additional rival meningitis vaccines from Novartis, namely Menveo and Bexsero, the European Commission and other antitrust regulators were concerned that this gave GSK too much power in

  • Pharma deals in May 2015 Pharma deals in May 2015

    This will all be good practice for Teva as there will be considerable antitrust activity if the Teva-Mylan deal goes ahead.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics